This selection of transporters was chosen because they have proven to be important in drug disposition in adults or have shown a large abundancy in human adult liver (Hilgendorf et al., 2007) .
Children's growth and maturation importantly impact the processes involved in the disposition of drugs such as absorption, metabolism and renal excretion (Kearns et al., 2003) . It is therefore likely that expression and activity of transporters are also subject to age-related changes, as has been convincingly shown for the drug metabolizing enzymes, as reviewed by de Wildt (de Wildt, 2011) . Indeed, animal studies have shown transporter-specific maturation profiles in transporter expression as reviewed by Klaassen, Cui and Brouwer (Klaassen and Aleksunes, 2010; Cui et al., 2012; Brouwer et al., 2015) . For example, hepatic mRNA expression of mouse Oatps gradually increases after birth until adult levels at 6 weeks of age (Cheng et al., 2005) . In spite of the maturation in animal studies, interspecies differences prevent us to translate animal maturation data to humans (Wang et al., 2015) . For humans, only few transporters have been studied and two recent reviews showed that a clear information gap remains on the developmental trajectory of individual transporters in fetuses and young children and the related impact on drug disposition (Brouwer et al., 2015; Mooij et al., 2015) . Recently, we showed a transporter dependent maturation profile in mRNA expression of hepatic ABCB1, ABCC2, OATP1B1 and OATP1B3 (Mooij et al., 2014) . To predict drug disposition on the basis of these results is a challenge since posttranscriptional variation may result in a discrepancy between mRNA and protein levels, as has been shown for some transporters in human adults (Prasad et al., 2013; Ulvestad et al., 2013) . Protein expression data in children are limited. For example, a selection of transporters (ABCC2, ABCG2, ABCB1, OATP1B1, OATP1B3 and OATP2B1) has been quantified in children using quantitative LC-MS methods, but the younger age range (<7 years of age) where most developmental changes occur was not included in these studies (Deo et al., 2012; Prasad et al., 2013; Prasad et al., 2014) . Moreover, other pediatric transporter protein data are derived from non-quantitative immunohistochemistry studies (Brouwer et al., 2015) . The cohort of selected samples reflected a widespread gestational age (in second and third trimester of pregnancy), as well as postnatal age (up to three months) (age distribution is displayed in Figure 1 ). This step was repeated twice. Subsequently, 100 µL 0.05 M ammoniumbicarbonate was added to the concentrate and centrifuged (14,000g for 15 minutes). This step was also repeated twice.
Membrane isolation and Liquid Chromatography-Tandem Mass Spectrometry
Proteins were digested into peptides by incubating the samples overnight at 37°C in a 0.05 M ammoniumbicarbonate solution containing 0.5 µg/µL trypsin. The digests were collected into a new collection tube by centrifugation (14,000g for 10 minutes,) and the filter device was rinsed with 50 µL 0.5 M NaCl and centrifuged (14,000g for 10 minutes). The combined filtrate was acidified with 25 µL 0.1% CF 3 COOH, desalted on a 7 mm/ 3 mL extraction disk cartridge (3M Empore, Zoeterwoude, The Netherlands) and eluted with 70% acetonitrile. Subsequently, the samples were vacuum dried (SpeedVac) until the solution was vaporized and stored < -70°C until further analysis. 
Transporter protein expression from fetus to adult
The selected hepatic transporter proteins could be detected in all samples. There was a 10 to 300-fold relative difference in transporter protein abundance between the patients with the lowest and the highest protein expression (Figure 2 ). The highest variability was seen in GLUT1
protein expression with a nearly 300-fold relative difference. Table 2 shows the median abundance of studied transporters in fetal, infant and adult samples. With exploration of the relationship between age and protein expression four developmental patterns emerged. We describe these patterns, but they should be interpreted with care, as after correction for multiple
1 2 testing, only a consistent, significant age-effect remains for BSEP, ABCG2, GLUT1, MCT1. Table 3 shows the four developmental profiles in relation to previous results from other studies on transporter mRNA and protein expression. Protein expression levels in the age groups, postnatal age and postmenstrual age are shown in Table 2 , Figure 3 and Figure 4 , respectively.
First, in profile I ('stable') ABCB1, OATP1B1, OATP2B1 and ABCC2 protein expression levels appeared similar across the age groups and within the fetal and infant groups.
Next, in profile II ('low to high') ABCC3, and BSEP protein expression levels appeared low in fetus and higher in infants and adulthood. Median protein levels of ABCC3, and BSEP were approximately 4-fold, and 2-fold lower in fetuses than infants and adults respectively.
The opposite pattern appears for group III ('high to low'), for ABCG2, GLUT1, and OCTN2, with higher protein abundance early in life than at adult age was observed. This pattern was most striking for GLUT1 with more than 80 fold higher expression in fetus than adult, but less convincing for the ABCG2 and OCTN2 were the difference appears a magnitude 1,5-2 fold.
Within the young age group, expression levels appear more strongly correlated with postmenstrual than postnatal age.
Lastly, in profile IV ('non-linear') the MCT1 protein expression appeared to display a curvilinear relationship with postnatal age, with a 2-fold higher expression in infants than in both fetuses and adults. Within the fetal and infant groups, the MCT1 protein expression appeared to increase with postmenstrual age but this did not reach significance after correction for multiple testing.
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Correlation analysis of transporter protein abundances
To explore potentially shared expression regulation, Spearman correlations of transporter protein expression levels between transporters were performed. In total, the expression levels of 16 transporter-pairs were significantly correlated to each other (Table 4) Table 3 . While we recognize that animal data may provide important insights in maturational changes, we exclusively focus on human data as specific maturation patterns may be very different from animals.
Stable expression of hepatic transporters: Profile I
Protein expression of ABCB1, OATP1B1, OATP2B1 and ABCC2 transporters was similar in fetuses, infants and adults. For ABCB1, OATP1B1 and OATP2B1 this adds to current LC-MS/MS data on patients between 7-70 years of age (n=64), in which ABCB1, OATP1B1, and OATP2B1 protein expressions were also stable (Prasad et al., 2014) . However, for ABCC2
protein expression an increasing protein expression is previously reported (abstract only) (Tang, 2007) .
ABCB1 is the most studied transporter in fetuses and children. Examples of ABCB1 substrate drugs are digoxin, dexamethasone, tacrolimus, and morphine (Hebert, 1997; Ratnapalan et al., 2003; Kimura et al., 2007; Thorn et al., 2009) . Interestingly, our finding that ABCB1 protein expression data is consistent in the investigated age-ranges adds to other protein studies using immunoblotting in pediatric postmortem and living donors, in which stable protein expression was found from 0.3-12 years of age (abstract only) (Tang, 2007) . In contrast, this apparent stable ABCB1 protein expression differs from the previously reported immature ABCB1 mRNA expression in the first year of life (van Kalken et al., 1992; Miki et al., 2005; Fakhoury et al., 2009; Mooij et al., 2014; Burgess et al., 2015) . An explanation between these
1 5 discrepant results may reside in the observation in adults that ABCB1 mRNA and protein expressions were not correlated (Ulvestad et al., 2013) .
Similar OATP1B1 protein expression in the first months of life and adults contrasted from a study in 78 liver samples from children aged 0-12 years, in which the OATP1B1 protein expression by Western blotting was low from birth until 6 years of age and increased thereafter (abstract only) (Thomson et al., 2013 ). Yet, a smaller protein study using Western blotting on liver samples from neonates (n=5) and adults (n=5) confirms our finding regarding OATP1B1 (Yanni et al., 2011) . OATP1B1 mRNA expression data from several other cohorts do not correspond to our protein data, with low expression in fetuses and infants up to 1 year of age (n=32) (Sharma et al., 2013; Mooij et al., 2014; Burgess et al., 2015) .
Stable OATP2B1 protein expression in infants and adults contrasts to lower OATP2B1 mRNA expression in samples of fetuses (n=3) from the second trimester of pregnancy than in samples from adults (n=3) (Sharma et al., 2013) .
Our data for ABCC2 are less evident. While fetal expression appeared two-fold lower than adults, this difference was no longer significant after correction for multiple testing. Also within the fetal/infant group, expression was not significantly correlated with either postnatal or postmenstrual age. Using western blotting in children from 0-12 years of age, Tang et al. did
show an increase in protein levels (abstract only) (Tang, 2007) . In addition, other studies found lower ABCC2 mRNA expression in samples from fetuses and infants up to 1 year of age than in samples from adults (Mooij et al., 2014; Burgess et al., 2015) . Lower expression of ABCC3 early in life is not seen in a small study using liver samples of 5 neonates and 5 adults, in which relative ABCC3 protein expression using Western blotting was similar in both groups (Yanni et al., 2011) . In contrast, mRNA expression of ABCC3 in 3 fetal liver samples was significantly lower than that in 3 adult liver samples (Sharma et al., 2013) and in perinatal/neonatal liver samples (prenatal to postnatal day 30, n=6; and 0-4 years, n=8) compared to liver samples from children older than 7 years (Klaassen and Aleksunes, 2010).
High to low expression of hepatic transporters during childhood: Profile III
The ABCG2, GLUT1, and OCTN2 transporters appear to be higher early in life and lower at adult age. This adds to current data of stable protein expression from 7 years onwards (Prasad et al., 2013 (Sharma et al., 2013; Burgess et al., 2015) .
To the best of our knowledge, there are no human developmental expression data available for GLUT1 and OCTN2. The same holds for MCT1, which forms the fourth developmental profile group with non-linear expression profile amongst the three age categories.
The statistical analysis of these data to explore the relation with age posed an important challenge. While these patterns point towards age-dependent changes in transporter expression, our data sample was too small to explore the exact developmental patterns using different statistical models with an acceptable degree of certainty. Historically, pediatric dosing has been based on the assumption that adult doses could be adjusted linearly based on body weight. We now know that for most drugs this approach is inadequate as it does not take into 
Variability in transporter expression
This exploratory study confirms earlier reports of transporter-specific discrepancy between mRNA and protein expression. Our ABCB1, ABCG2, OATP1B1, OATP2B1 protein developmental patterns do not seem to correspond to earlier mRNA expression data (Yanni et al., 2011; Sharma et al., 2013; Mooij et al., 2014) . This discrepancy shows the relative weakness of relying solely on mRNA expression data to understand transporter maturation. An explanation could be posttranscriptional changes -for example mediated by microRNAs -on account of which mRNA does not correspond to protein expression (Koturbash et al., 2012) .
Recently, developmental changes in hepatic miRNA expression have been shown, and for some, miRNA expression was correlated to mRNA expression of drug disposition genes (Burgess et al., 2015) . The interpretation of protein data should also be done with care, as transporter protein expression itself may not necessarily translate to transporter activity.
Glycosylation, phosphorylation, and ubiquination, might alter proteins into active or non-active forms (Klaassen and Aleksunes, 2010).
It can be speculated that the maturation of transporter expression is in line with the physiological transporter function with respect to growth and development. For example, transporters that are involved in energy supply in fetal life may be up regulated in fetuses and early in life. Glucose transporter GLUT1 and L-carnitine (molecule that shuttles long-chain fatty acids to the mitochondria for oxidation) transporter OCTN2, are probably both essential for fetal energy supply, which seems to tally with our findings of high protein expression in fetuses and early in life. On the other hand, transporters involved in the uptake and efflux of steroids and bilirubin (i.e. OATPs, MRP2), may show less variability throughout life.
We hypothesized that pairwise-correlation in transporter expression might reveal a common developmental origin and point towards interlinked physiological processes. We found (Achour et al., 2011; Achour et al., 2014a; Achour et al., 2014b ). To our knowledge, these inter-transporter correlations at the protein level have not been described previously. Many drugs have been shown to be substrates for multiple transporters, which may result in compensatory pathways in case a specific transporter is inactive due to genetic variation or drug-drug interactions. In addition, hepatocyte-hopping of substrates using different transporters may enhance efficient hepatic drug clearance (Iusuf et al., 2012) .
Therefore, when using transporter expression data to predict drug disposition it is recommended to consider drug transport, and also drug metabolism as an interrelated biological system.
Variability in transporter expression may also be explained by other factors than age, such as disease, genetic heterogeneity, gender, drug-drug and drug-food interactions. This may explain some of the discrepancy between studies, as the sample origin and clinical characteristics are often only sparsely described. In human hepatocytes, inflammation via interferon-γ resulted in reduced mRNA expression of ABCB1, ABCC2, OATP1B1 and OATP2B1 (Le Vee et al., 2011) . More specifically in pediatric patients (1-2 months of age) with biliary atresia, hepatic ABCC2, BSEP, ABCB4, OATP1B1, OATP1B3, but not ABCC3 mRNA expression differed significantly from that in both fetuses and adults (Chen et al., 2008 Eventually, transporter maturation profiles and their interrelation may serve as input for physiologically-based pharmacokinetic (PBPK) models, which can be applied to use existing juvenile infant and human adult pharmacokinetic information to predict pharmacokinetics and drug response in children (Johnson et al., 2006; Bosgra et al., 2014 ).
In conclusion, we revealed age-dependent differences in absolute protein expression levels of ten different hepatic transporter proteins, with four developmental patterns emerging.
These findings are important as they strongly suggest that disposition of drugs and endogenous transporter substrates will be subject to age-related changes, which could impact the efficacy and safety of drugs in the first months of life. Organized by developmental profile groups (I to IV). 
